Evaluation of a new glucometer compared to a trusted lab method: improving accuracy in diabetes monitoring

Evaluation of Novel Glucometer in Pakistan

Abstract

Objective: Accurate blood glucose monitoring is vital for effective diabetes management, as it guides treatment decisions and helps prevent complications.
Study design: The aim of this study was to evaluate the accuracy and reliability of a new personal glucometer, MedSenso (MS), by comparing its glucose readings with those from the standard Cobas Pro laboratory analyzer.
Place and duration of study: The multicentered study was conducted at Islamabad Diagnostic Center Pakistan, having over during Nov 2024 to Mar 2025 after ethical approval.
Patients and Methods: We tested 200 venous blood samples from diabetic patients using both devices.
Results: The results demonstrated a strong correlation between MedSenso and Cobas Pro, with a Pearson correlation coefficient of r = 0.978. The Cobas Pro measured an average glucose level of 208.40 mg/dL, while MedSenso showed a slightly lower average of 198.06 mg/dL. The standard deviations were 90.27 mg/dL and 85.33 mg/dL, respectively, indicating slightly more consistent readings from MedSenso. Bland–Altman analysis showed that the differences between devices were small and within clinically acceptable limits, suggesting that the variation is unlikely to impact routine patient care.
Conclusion: These findings suggest that MedSenso provides glucose measurements comparable to those of a laboratory-grade analyzer. Given its ease of use and rapid results, MedSenso could be a dependable tool for point-of-care monitoring in clinics and home settings. However, laboratory confirmation is recommended when highly precise glucose values are critical for clinical decisions.